105 related articles for article (PubMed ID: 21812901)
1. The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years.
Hayashi N; Matsushima M; Yamamoto T; Sasaki H; Takahashi H; Egawa S
BJU Int; 2012 Feb; 109(4):515-9. PubMed ID: 21812901
[TBL] [Abstract][Full Text] [Related]
2. The uncertain relationship between obesity and prostate cancer: an Italian biopsy cohort analysis.
De Nunzio C; Freedland SJ; Miano L; Finazzi Agrò E; Bañez L; Tubaro A
Eur J Surg Oncol; 2011 Dec; 37(12):1025-9. PubMed ID: 21963050
[TBL] [Abstract][Full Text] [Related]
3. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer.
Ochiai A; Fritsche HA; Babaian RJ
Urology; 2005 Oct; 66(4):819-23. PubMed ID: 16230145
[TBL] [Abstract][Full Text] [Related]
4. [Clinical impact of body mass index on prostate biopsy in patients with intermediate PSA levels].
Sekita N; Suzuki H; Kamijima S; Chini K; Fujimura M; Mikami K
Hinyokika Kiyo; 2008 Jul; 54(7):479-83. PubMed ID: 18697492
[TBL] [Abstract][Full Text] [Related]
5. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
6. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
7. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
8. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
9. Impact of common medications on serum total prostate-specific antigen levels and risk group assignment in patients with prostate cancer.
Nieder C; Norum J; Geinitz H
Anticancer Res; 2011 May; 31(5):1735-9. PubMed ID: 21617232
[TBL] [Abstract][Full Text] [Related]
10. The influence of statin medications on prostate-specific antigen levels.
Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ
J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682
[TBL] [Abstract][Full Text] [Related]
11. Relationship between prostate-specific antigen bounce body fat distribution and body mass index in permanent seed brachytherapy for prostate cancer.
Delouya G; Taussky D; Ji CR; Sylvestre MP; Donath D
Brachytherapy; 2012; 11(3):214-8. PubMed ID: 21700507
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
13. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
[TBL] [Abstract][Full Text] [Related]
14. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
15. Body mass index as a predictor of prostate cancer: development versus detection on biopsy.
Freedland SJ; Terris MK; Platz EA; Presti JC
Urology; 2005 Jul; 66(1):108-13. PubMed ID: 15992911
[TBL] [Abstract][Full Text] [Related]
16. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
Makarov DV; Sanderson H; Partin AW; Epstein JI
J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
[TBL] [Abstract][Full Text] [Related]
17. Hypertriglyceridemia as a possible risk factor for prostate cancer.
Wuermli L; Joerger M; Henz S; Schmid HP; Riesen WF; Thomas G; Krek W; Cerny T; Gillessen S
Prostate Cancer Prostatic Dis; 2005; 8(4):316-20. PubMed ID: 16158078
[TBL] [Abstract][Full Text] [Related]
18. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.
Krane LS; Menon M; Kaul SA; Siddiqui SA; Wambi C; Peabody JO; Agarwal PK
Urol Oncol; 2011; 29(4):372-7. PubMed ID: 19576796
[TBL] [Abstract][Full Text] [Related]
19. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
20. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
